Related by context. All words. (Click for frequent words.) 75 Carfilzomib 75 perifosine 74 Bortezomib 74 MGCD# [001] 71 Blinatumomab 71 Amrubicin 71 HGS ETR1 71 ganetespib 71 Voreloxin 71 histone deacetylase HDAC inhibitor 71 Hsp# Inhibitor 70 IMC A# 70 Elesclomol 70 Aflibercept 70 OncoVEX GM CSF 70 HDAC Inhibitor 70 Tanespimycin 70 Archexin 70 AP# [003] 70 Omacetaxine 70 Sapacitabine 70 investigational humanized monoclonal antibody 69 FOLOTYN ® 69 Golimumab 69 radiation sensitizer 69 BAY #-# 69 PXD# 69 sodium glucose cotransporter 69 Pralatrexate 69 Bafetinib 69 JAK inhibitor 69 MEK inhibitors 69 proteasome inhibitor 69 Bavituximab 69 Panzem R NCD 69 Cloretazine ® 69 Tamibarotene 69 Traficet EN 69 Atiprimod 69 voreloxin 69 vascular disrupting agent 68 mertansine 68 Ambrisentan 68 Romidepsin 68 Panitumumab 68 orally administered inhibitor 68 Daclizumab 68 HGS ETR2 68 CYC# 68 Panzem R 68 Maribavir 68 anti leukemic 68 Glufosfamide 68 OXi# 68 Phase 2b Clinical Trial 68 proteasome inhibitors 68 Darinaparsin 68 Epratuzumab 68 Azedra 68 Bevacizumab 68 targeting CD# 68 Tesetaxel 68 Azixa 68 Irinotecan 68 Bezielle 68 Ofatumumab 68 mapatumumab 68 Dapagliflozin 68 oral prodrug 68 INCB# [001] 68 PSN# [002] 68 TAFA# 68 liposomal formulation 68 alvespimycin 68 CR# vcMMAE 68 Pivotal Phase III 68 receptor tyrosine kinase inhibitor 67 Xanafide 67 Apaziquone 67 anticancer compound 67 Tyrima 67 signal transduction inhibitor 67 KRN# 67 HER2 positive metastatic breast 67 tumor vascular disrupting 67 CA4P 67 AEG# 67 PS# [001] 67 Pazopanib 67 Tezampanel 67 oral proteasome inhibitor 67 Cetrorelix 67 Talabostat 67 LEP ETU 67 AEGR 67 HuMax CD4 67 Randomized Phase 67 MEK inhibitor 67 Radezolid 67 PEG SN# 67 hematological malignancies 67 PNP inhibitor 67 PRTX 67 Meets Primary Endpoint 67 Akt inhibitor 67 phase IIb clinical 67 CCX# 67 HDAC inhibitor 67 Oritavancin 67 Cyclooxygenase Inhibiting Nitric Oxide 67 dasatinib Sprycel ® 67 YONDELIS 66 Aplidin 66 Phase III Clinical Trial 66 Antiangiogenic 66 obatoclax 66 selective kinase inhibitor 66 investigational compound 66 XL# [003] 66 Belinostat 66 erlotinib Tarceva ® 66 Alemtuzumab 66 orally bioavailable 66 Cloretazine R 66 investigational monoclonal antibody 66 PLK1 SNALP 66 TREANDA 66 Palifosfamide 66 imatinib Gleevec ® 66 IAP inhibitors 66 Nexavar ® 66 Civacir 66 Dasatinib 66 EOquin TM 66 NXL# 66 iSONEP 66 Phase IIb Trial 66 oxidative stress inducer 66 anticancer agent 66 rNAPc2 66 Æterna Zentaris 66 sorafenib tablets 66 Telaprevir 66 AMN# [001] 66 Elotuzumab 66 PDX pralatrexate 66 Ceflatonin R 66 Antitumor Activity 66 Phase #b/#a clinical 66 Clinical Trial Results 66 RGB # 66 protein kinase inhibitor 66 MEK Inhibitor 66 INCB# [002] 66 Mipomersen 66 #ME# 66 metaglidasen 66 multi kinase inhibitor 66 AEZS 66 Elagolix 66 axitinib 66 ENMD 66 Seliciclib 66 Marqibo 66 PDE4 inhibitor 66 Cloretazine R VNP#M 66 OMP #M# 66 forodesine 66 Metastatic Melanoma 66 XL# anticancer compounds 66 class mGluR5 inhibitor 66 Pivotal Phase 66 polymerase inhibitor 66 pomalidomide 65 Epidermal Growth Factor Receptor 65 Annamycin 65 ARRY # 65 Hedgehog Pathway Inhibitor 65 CTAP# Capsules 65 Sym# 65 Afatinib 65 CYT# potent vascular disrupting 65 Ozarelix 65 HuMax EGFr 65 Cethromycin 65 generation Hsp# inhibitor 65 tanespimycin 65 2 methoxyestradiol 65 Vicinium TM 65 pan HDAC inhibitor 65 AKT inhibitor 65 Cloretazine 65 glufosfamide 65 Anti Tumor 65 Vandetanib 65 JAK1 65 Deforolimus 65 Boceprevir 65 Pixantrone 65 Satraplatin 65 PI3K/Akt pathway inhibitor 65 Aurora Kinase 65 Pemetrexed 65 ALN TTR 65 bevacizumab Avastin ® 65 ASONEP 65 HGS# 65 Clofarabine 65 ThermoDox R 65 AQ4N 65 R roscovitine 65 Serdaxin 65 Pafuramidine 65 somatostatin analogue 65 TKB# 65 carfilzomib 65 Pirfenidone 65 XL# XL# 65 Erlotinib 65 virus HCV protease inhibitor 65 Lubiprostone 65 Ridaforolimus 65 Virulizin ® 65 amrubicin 65 Talactoferrin 65 DOXIL 65 tezampanel 65 Phase Ib 65 Phase 2b Study 65 Dalbavancin 65 relapsed refractory multiple myeloma 65 Advanced Renal Cell 65 Pathway Inhibitor 65 Peginterferon 65 R#/MEM # 65 BZL# 65 Arimoclomol 65 Darusentan 65 huC# DM4 65 depsipeptide 65 Imprime PGG 65 EZN 65 Combination REOLYSIN R 65 oral anticancer 65 novel histone deacetylase 65 novel VDA molecule 65 Phase 2a Clinical Trial 65 elotuzumab 65 Anti Tumor Activity 64 Capecitabine 64 PF # [001] 64 favorable pharmacokinetic profile 64 sorafenib Nexavar 64 EGFR HER2 64 CCR5 antagonist 64 CCR9 antagonist 64 Phase Ib clinical 64 hematologic malignancies 64 registrational trial 64 Antiviral Activity 64 tyrosine kinase inhibitor 64 Zolinza 64 JAK Inhibitor 64 Xcytrin 64 small molecule Hedgehog 64 Phase Ib II 64 refractory chronic lymphocytic 64 TELINTRA 64 Allovectin 7 R 64 Exelixis compounds 64 Naproxcinod 64 Genasense R 64 TYKERB 64 Genasense ® 64 Varespladib 64 Preclinical Data 64 SCH # 64 Proxinium TM 64 Onconase 64 selective androgen receptor modulator 64 Ceflatonin 64 histone deacetylase inhibitor 64 Nimotuzumab 64 Phase IIb Clinical Trial 64 seliciclib 64 HSP# inhibitor 64 targeted radiotherapeutic 64 HspE7 64 delafloxacin 64 brostallicin 64 elacytarabine 64 PEGylated Fab fragment 64 ixabepilone 64 humanized anti 64 RDEA# 64 mitogen activated ERK kinase 64 Phase 2a Trial 64 RNAi Therapeutic 64 mGluR5 negative 64 Aplidin R 64 Alpharadin 64 Allovectin 7 ® 64 SARMs 64 IL# PE#QQR 64 CBLC# 64 #D#C# 64 ELND# 64 Fidaxomicin 64 CORT # 64 Albuferon TM 64 Pertuzumab 64 Methylnaltrexone 64 Everolimus 64 ENMD # 64 Metastatic Colorectal Cancer 64 mTOR inhibitor 64 small molecule chemotherapeutic 64 JAK2 inhibitor 64 TOCOSOL Paclitaxel 64 Gemzar ® 64 IMGN# 64 vascular disrupting agents 64 sunitinib malate 64 Initiate Phase 64 Vilazodone 64 Clevudine 64 MGCD# [002] 64 seliciclib CYC# 64 Tolvaptan 64 anticancer therapy 64 non nucleoside inhibitor 64 Alocrest 64 Silodosin 64 Investigational Compound 64 Mitoxantrone 64 SUTENT 64 Phase Ib clinical trials 64 unique alkylating agent 64 sunitinib Sutent ® 64 Aliskiren 64 IgG1 monoclonal antibody 64 Serdaxin ® 64 fosbretabulin 64 BiovaxID TM 64 NEUGENE 64 Completes Patient Enrollment 64 AVN# [001] 64 ON #.Na 64 relapsed multiple myeloma 64 Apixaban 64 Eltrombopag 64 Pharmacokinetics PK 64 OvaRex R 64 INCB# [003] 63 ISIS # 63 CIMZIA TM 63 Laquinimod 63 CD# monoclonal antibody 63 Ceftaroline 63 romidepsin 63 talactoferrin 63 torezolid phosphate 63 Virulizin R 63 CCX# B 63 MAGE A3 ASCI 63 Doxorubicin 63 Drug Candidate 63 nucleoside reverse transcriptase inhibitor 63 Sphingomab 63 eniluracil 63 EndoTAG TM -1 63 Chemophase 63 Panzem NCD 63 nucleoside analog 63 Previously Treated 63 generation proteasome inhibitor 63 Well Tolerated 63 Gemcitabine 63 talabostat 63 GRN#L 63 atacicept 63 XL# XL# XL# XL# 63 XYOTAX TM 63 Icatibant 63 PCK# 63 Exherin TM 63 PEG Interferon lambda 63 Tarvacin TM 63 immunomodulating 63 Tipranavir 63 novel tubulin binding 63 pertuzumab 63 anti amnesic 63 Phase III Trial 63 evaluating Xcytrin 63 T DM1 63 alkylating agent 63 Personalized Immunotherapy 63 aflibercept 63 IMPDH inhibitor 63 ATL/TV# 63 JAK2 Inhibitor 63 Diabetic Macular Edema 63 humanized monoclonal antibody 63 ularitide 63 PKC# 63 Allovectin 7 63 refractory multiple myeloma 63 Vidofludimus 63 GRN# 63 Presents Preclinical Data 63 Picoplatin 63 IAP inhibitor 63 IMA# 63 Delafloxacin 63 LibiGel ® 63 Calcitonin 63 immunotherapeutic agent 63 vinca alkaloids 63 CD3 monoclonal antibody 63 AMD# [003] 63 HQK 63 Monotherapy 63 Aurora kinase 63 Pivotal Trial 63 bevacizumab Avastin 63 VAPRISOL 63 Exelixis XL# 63 Trodusquemine MSI 63 satraplatin 63 Perifosine KRX 63 resistant ovarian cancer 63 Brentuximab Vedotin SGN 63 tamibarotene 63 Indaflex TM 63 HCV protease 63 eltrombopag 63 anticancer agents 63 Linaclotide 63 APOPTONE 63 thymalfasin 63 small molecule tyrosine 63 peripherally acting 63 blinatumomab 63 Peginterferon alfa 2b 63 oral isoform selective HDAC 63 Squalamine 63 oral ridaforolimus 63 BAL# [002] 63 metastatic renal cell carcinoma 63 refractory Hodgkin lymphoma 63 antitumor activity 63 Docetaxel 63 preclinical efficacy 63 CYT# 63 RG# [001] 63 relapsed ovarian cancer 63 lintuzumab 63 evaluating tivozanib 63 CRx 63 Tarceva TM 63 TRX1 63 Romiplostim 63 Fulvestrant 63 kinase inhibitor 63 ongoing Phase 1b 63 Bicifadine 63 INT# [002] 63 endothelin receptor antagonists 63 Iloperidone 63 vosaroxin 63 Investigational Drug 63 fluoroquinolone antibiotic 63 Enzastaurin 63 Muraglitazar 63 apoptosis inducer 63 MDV# 63 cetuximab Erbitux R 63 dacetuzumab 63 ProLindac 63 LY# [003] 63 cilengitide 63 Granulocyte Colony Stimulating Factor 63 Microplasmin 63 ATL# [001] 63 novel immunomodulatory 63 TBC# 63 LymphoStat B belimumab 63 Investigational Agent 63 TELCYTA 63 HCD# [002] 63 MEK inhibitor RDEA# 63 REP# 62 Indibulin 62 Androgen Receptor 62 enzastaurin 62 NGX# 62 pralatrexate 62 Eculizumab 62 Gefitinib 62 sulodexide 62 Denufosol 62 MOZOBIL 62 NEUMUNE 62 trastuzumab DM1 T DM1 62 DXL# 62 belinostat 62 JAK inhibitors 62 Novel Oral 62 angiogenesis inhibitor 62 Oral Fingolimod 62 cediranib 62 Aurexis 62 PLX# 62 Panzem 62 cancer mCRC 62 class anticancer quinolone 62 MBP# [001] 62 galiximab 62 XmAb# 62 Raltegravir 62 hematological cancers 62 ELACYT 62 Phase III Pivotal 62 Phase Ib study 62 angiotensin receptor blocker ARB 62 pralatrexate injection folate analogue 62 SAR# [004] 62 non nucleoside HCV 62 Cannabinor 62 ara C 62 CoFactor 62 IMiDs R 62 Phenoptin 62 Cutaneous T 62 XL# XL# XL# 62 Vicriviroc 62 Demonstrates Potent 62 L Annamycin 62 Prolongs Survival 62 clofarabine 62 sapacitabine 62 Patient Enrollment 62 vidofludimus 62 olaparib 62 immunomodulator 62 alfa 2a 62 HRPC 62 TACI Ig 62 phase IIa clinical 62 Investigational Treatment 62 Symadex 62 Novel Mechanism 62 Ustekinumab 62 NKTR 62 TMC# [002] 62 Phase 2b Trial 62 MORAb 62 novel anticancer 62 TRAIL receptor antibodies 62 LHRH antagonist 62 Solazed TM 62 Phase III Trials 62 acyclovir Lauriad R 62 ASA# 62 AZD# 62 selective modulator 62 neratinib 62 Hematological Malignancies 62 Elvitegravir 62 Phase 1b Clinical Trial 62 ceftazidime 62 dasatinib Sprycel 62 microtubule targeting 62 Degarelix 62 Bucindolol 62 Lacosamide 62 Ceftobiprole 62 anticancer therapies 62 TORISEL 62 Troxatyl 62 Plicera 62 TNF Tumor Necrosis Factor 62 ZOLINZA 62 Cisplatin 62 SPRYCEL ® 62 BiTE antibody 62 Etoposide 62 PSMA ADC 62 Bosutinib 62 investigational pan BCR 62 Thiarabine 62 ZK EPO 62 DB# [003] 62 Debio 62 Doxil ® 62 ALN PCS 62 peptidic compound 62 monoclonal antibody conjugated 62 pseudobulbar affect PBA 62 Exherin 62 Herceptin trastuzumab 62 Nitazoxanide 62 Nilotinib 62 nucleoside analogue 62 IRX 2 62 BAL# [001] 62 Amigal 62 leading oral taxane 62 Ocrelizumab 62 Marqibo TM 62 antibody MT# 62 compound INCB# 62 Tyrosine Kinase Inhibitor 62 TG# [003] 62 antibody MAb 62 Orphan Drug designations 62 EGFR inhibitors 62 indibulin 62 CD# antibody [001] 62 FOLFOX6 62 CEQ# 62 Phase III Clinical Trials 62 Factor Receptor 62 OvaRex ® MAb 62 fluoropyrimidine 62 ISTODAX 62 tiapamil 62 Tocilizumab 62 selective inhibitor 62 docetaxel Taxotere R 62 polymerase inhibitors 62 Medullary Thyroid Cancer 62 LE SN# 62 nab paclitaxel 62 small molecule activator 62 Hsp# inhibitors 62 Anti TNF 62 rilonacept 62 Cetrorelix pamoate 62 Kinase Inhibitor 62 elvitegravir 62 combretastatin A4 phosphate CA4P 62 Nanobody 62 Telbivudine 62 ONCONASE 62 DU #b 62 Copegus ribavirin 62 Preclinical studies suggest 62 Angiolix 62 PSN# [001] 62 oncology indications 62 CB2 selective receptor agonist 62 docetaxel Taxotere ® 62 Initiates Phase III 62 BrachySil 62 Inhibitor 62 atrial fibrillation budiodarone ATI 62 sorafenib Nexavar ® 62 UPLYSO 62 TriRima 62 Anthracyclines 62 BRAF inhibitor 62 alvimopan 62 Anticancer Compound 62 Factor VIIa 62 Crizotinib 62 SNT MC# 62 Onco TCS 62 MyVax R 62 Intravenous CP 62 Zoraxel 62 Safinamide 62 mRCC 62 MGd 62 ProLindac TM 62 Reolysin 62 inhibits Akt activation 62 Universal Flu Vaccine 62 MT# MEDI 62 Octreotide 62 telaprevir VX 62 Phase 1b 62 adecatumumab 62 Avanafil 62 Phase 2a 62 Granted Orphan Drug 61 Pradefovir 61 Tolerability 61 Hormone Refractory Prostate Cancer 61 HCV protease inhibitors 61 immunomodulatory 61 PRT# 61 dose escalation Phase 61 Interferon Beta 61 deforolimus 61 Tigecycline 61 Azacitidine 61 nitazoxanide 61 HCV protease inhibitor 61 Teriflunomide 61 LymphoStat B TM 61 glioblastoma multiforme GBM 61 HCV SPRINT 61 Phase 2b 61 PARP inhibitor 61 Phase 1b trial 61 B CLL 61 pharmacokinetic PK study 61 5 HT3 antagonist 61 Immunotherapeutic 61 celgosivir 61 Neulasta ® 61 ONX 61 biologic therapy 61 adalimumab Humira 61 ARRY 61 nilotinib Tasigna ® 61 Telavancin 61 DAVANAT R 61 Pimavanserin 61 Clolar ® 61 entinostat 61 Luteinizing Hormone Releasing Hormone 61 novel nucleoside analog 61 Adalimumab 61 TRO# 61 perifosine KRX 61 cutaneous T cell 61 CCR2 61 Initiate Phase III 61 Camptosar ® 61 lenalidomide Revlimid R 61 Lenocta TM 61 EOquin 61 Cintredekin Besudotox 61 Tofacitinib 61 Pivotal Phase II 61 metastatic hormone refractory 61 metastatic castrate resistant 61 highly selective inhibitor 61 gemcitabine Gemzar 61 Sudhir Agrawal D.Phil 61 PREZISTA r 61 IMiDs ® 61 Alfimeprase 61 evaluating picoplatin 61 ADP receptor antagonist 61 bendamustine 61 Hepatocellular Carcinoma 61 Imatinib 61 Tumor Necrosis Factor 61 ANG# 61 Renal Cell Carcinoma 61 Phase #/#a trial 61 panitumumab Vectibix 61 gastrointestinal stromal tumors GIST 61 Paclitaxel Carboplatin 61 SUTENT ® 61 taxanes 61 Randomized Phase II 61 Preclinical Efficacy 61 superficial bladder cancer 61 otelixizumab 61 Curaxin 61 Pharmacokinetic Study 61 Sorafenib 61 TYZEKA 61 Guanilib 61 molecularly targeted 61 Pegylated 61 PEGylated interferon beta 1a 61 Paraplatin ® 61 Peginterferon Alfa 2b 61 CDK inhibitor 61 ISENTRESS 61 direct thrombin inhibitors 61 Phase 1b clinical 61 MET amplification 61 VEGF Trap 61 IMC #B 61 INC# 61 Pivotal Study 61 OHR/AVR# 61 vorinostat 61 MAP# 61 ofatumumab 61 Xeloda ® 61 phase Ib 61 Rituximab 61 drug pipeline TAFA# 61 Natalizumab 61 rALLy clinical trial 61 Trial Evaluating 61 ozarelix 61 LHRH antagonists 61 Belimumab 61 Myelofibrosis 61 ALN TTR# 61 tocilizumab 61 sunitinib 61 Rexin G 61 alpha 2a 61 DermaVir Patch 61 dirucotide MBP# 61 SinuNase TM 61 metastatic HRPC 61 Chemokine Receptor 61 Hsp# inhibition 61 ZADAXIN ® 61 xenograft models 61 Fondaparinux 61 Chronic Lymphocytic Leukemia CLL 61 RhuDex ® 61 Randomized Double blind 61 tipifarnib 61 bortezomib Velcade R 61 sunitinib Sutent 61 demonstrated antitumor activity 61 cell lymphoma CTCL 61 NS4A 61 nucleoside analogues 61 Phase IIa trial 61 Zoraxel ™ 61 Initiates Clinical 61 Lenalidomide 61 ANYARA 61 ThermoDox ® 61 GV# [001] 61 Thiovir 61 Tarvacin 61 Protexia R 61 Successfully Completes Phase 61 Phase 1b clinical trials 61 generation nucleoside analog 61 Trastuzumab 61 Long Term Efficacy 61 candidate deforolimus 61 Pulmonary Arterial Hypertension 61 vinca alkaloid 61 R lenalidomide 61 tesmilifene 61 ocular formulation 61 ATL# [002] 61 BCX# 61 NDA Submission 61 carboplatin paclitaxel 61 relapsed MM 61 Protease Inhibitor 61 BNC# 61 PROSTASCINT R 61 Fodosine 61 SERMs 61 GMX# 61 dirucotide 61 preclinically 61 vemurafenib 61 visilizumab 61 Tasigna nilotinib 61 Chronic Lymphocytic Leukemia 61 YONDELIS R 61 2 inhibitor CYT# 61 Rigel R# 61 alpha folate receptor 61 taxane 61 oral rivaroxaban 61 potent inhibitor 61 NVA# 61 Argatroban 61 radezolid 61 NS#/#A protease 61 ulimorelin 61 Gleevec resistant 61 Pegloticase 61 ISTODAX ® 61 HGS ETR1 mapatumumab 61 II Clinical Trial 61 multitargeted 61 OMAPRO 61 Curaxin CBLC# 61 cetuximab Erbitux 61 registrational 61 orally dosed 61 leukemia AML 61 nucleoside 61 EP #R 61 delta isoform 61 lumiliximab 61 immunotherapeutic 61 refractory acute myeloid 61 phase IIb trial 61 LUX Lung 61 XP# XP# 61 oncolytic vaccine 61 oral FTY# 61 Keryx Biopharma 61 chemopreventive agent 61 5 HT6 receptor 61 Obatoclax 61 limiting toxicity 61 idarubicin 61 Statistically Significant 61 GW# [003] 61 perifosine novel potentially 61 lintuzumab SGN 61 investigational oral inhibitor 61 Stedivaze 61 6R BH4 61 TEMODAL 61 GALNS 60 aflibercept VEGF Trap 60 sorafenib Nexavar R 60 Ticagrelor 60 Small Molecule 60 LE DT 60 Velcade bortezomib 60 potent antiproliferative 60 Receptor Antagonists 60 novel topoisomerase 60 Lenocta 60 systemically administered 60 hormone LHRH antagonist 60 Avastin bevacizumab 60 AzaSite Plus 60 bosutinib 60 metastatic castration resistant 60 AVE# 60 reversible inhibitor 60 poly ADP ribose polymerase 60 OncoVEX 60 NP2 Enkephalin 60 CK # novel 60 MTP inhibitor 60 Zerenex 60 Dose Escalation 60 BRIM2 60 PEG IFN 60 Fx #A 60 Xyfid TM 60 Tavocept 60 cetuximab Erbitux ® 60 Ecallantide 60 LY# [002] 60 Treanda 60 Dacogen injection 60 REOLYSIN ® 60 TLR8 agonist 60 Zoraxel TM 60 tigecycline 60 regorafenib 60 romiplostim 60 Quinamed 60 liposomal doxorubicin 60 Taxotere R 60 insulin sensitizers 60 EGFR expressing mCRC 60 anti EGFR antibody 60 oral nucleoside analogue 60 rxRNA 60 Onalta 60 RE SURGE 60 Ixempra 60 PROCHYMAL 60 decitabine 60 panobinostat 60 FDA Orphan Drug 60 CD4 monoclonal antibody 60 platinum refractory 60 Janus kinase 60 ALN RSV# 60 ANAVEX #-# [001] 60 insulin sensitizing 60 Telatinib 60 Valsartan 60 albinterferon alfa 2b 60 L BLP# 60 PARP inhibitors 60 p# inhibitor 60 Fast Track Status 60 OMNARIS HFA 60 Triolex 60 ATG Fresenius S 60 mGluR5 NAM 60 Vidaza azacitidine 60 Epothilones 60 allosteric modulator NAM 60 CINOD 60 ACHN 60 Liposomal 60 trastuzumab Herceptin R 60 Ixabepilone 60 VEGFR2 inhibitor 60 Initiates Phase 60 RNAi Therapeutics 60 MVA BN R 60 Neuradiab 60 Phase 2b clinical trials 60 palifosfamide Zymafos TM 60 Orphan Drug